Skip to main content

Virtual visit appointments available 7 days a week from 9:00am to 11:00pm. Learn More

COVID-19 Updates

COVID-19 Updates: Get the latest on vaccine information, in-person appointments, virtual visits and more. Learn More

Andras Heczey


Texas Medical Center

Cancer and Hematology
Phone: 832-822-4242
Fax: 832-825-1453


1102 Bates Ave., Ste. 1760.10
Houston, TX 77030

Research Laboratory

Andras A. Heczey, MD

Director, Liver Tumor Program
Associate Professor, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine


School Education Degree Year
Baylor College of Medicine Fellowship Pediatric Hematology Oncology 2012
Children's Hospital of Los Angeles Residency Pediatrics 2009
Semmelweis Medical University, Hungary Residency Infectious Disease 2006
Semmelweis University Medical School Doctor of Medicine 2002


Dr. Andras Heczey is a physician-scientist and full-time faculty in the Department of Pediatrics of Baylor College of Medicine, Section of Pediatric Hematology/Oncology. He is a member of the multidisciplinary solid tumor team and the Center for Cell and Gene Therapy (CAGT).

News Articles

New Approach for Liver Cancer 


Organization Name Role
American Society of Cell and Gene Therapy (ASCGT) Member
American Society of Clinical Oncology (ASCO) Member
American Society of Pediatric Hematology and Oncology (ASPHO) Member
Children's Oncology Group (COG) Member

Research Statement

Dr. Andras Heczey's research focuses on developing novel treatments for children with solid tumors by redirecting the immune system to attack and kill cancer cells by using genetically-engineered T cells and Natural Killer T cells.

As the Director of the Liver Tumor Center, Dr. Heczey developed a strategy to target hepatoblastoma and hepatocellular carcinoma with genetically-engineered T lymphocytes. He is currently optimizing this strategy for a smooth transition into the clinic. He developed bispecific T cell engagers and chimeric antigen receptors which specifically target hepatoblastoma and hepatocellular carcinoma when expressed in T cells. His goal is to cure all patients with liver cancers by translating these methods from the laboratory setting to the patient care clinic. He was the corresponding author of Glypican-3-specific CAR T cells co-expressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma, one of the most highly cited Cancer Immunology Research articles published in 2020 and 2021.

In regards to neuroblastoma, Dr. Heczey studied and published the first adoptive immunotherapy approach utilizing Natural Killer T cells (NKT cells) that are genetically-modified to attack neuroblastoma. He aims to transition this approach from bench-to-bedside as a Phase 1/2a clinical trial.

Awards & Honors

2000              Good Student and Good Athlete of the Republic of Hungary, Ministry of Education of Hungary
2009              Associates and Affiliates Award of the Children's Hospital of Los Angeles, for scientific knowledge, clinical judgment and excellence in human relations
2010              Tumor Board Award, Texas Children's Cancer and Hematology Center
2011-2012     Chief Fellow, Texas Children's Cancer and Hematology Center
2015              Fellows’ Excellence in Education Award, Texas Children's Cancer and Hematology Center
2017              Faculty Recognition Award, Texas Children’s Cancer and Hematology Center
2017              Biotherapeutics Award, Alex's Lemonade Stand Foundation 

Board Certification

American Board of Pediatrics - General Pediatrics, American Board of Pediatrics - ​​​​​​​Pediatric Hematology and Oncology



Latest Videos

Liver Tumor Program at Texas Children's Cancer Center

TARE procedure available for pediatric liver cancer patients at Texas Children's Hospital

* Texas Children's Hospital physicians' licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician's office and were not verified by Texas Children's Hospital.